I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Phillip Pang Biography and Net Worth

Insider of Vir Biotechnology

Dr. Pang serves as Chief Medical Officer for Vir, where he is responsible for overseeing the Company’s global clinical development portfolio. His career in industry has been dedicated to the development of novel therapies to address some of the world’s most challenging infectious diseases. Since joining the company in 2016, Dr. Pang has advanced numerous compounds through early- mid- and into late-stage clinical development, including the company’s lead SARS-CoV-2 candidate, VIR-7831, which moved into Phase 3 in October 2020.

Prior to joining Vir, Dr. Pang served as Chief Medical Officer of Riboscience LLC, a Roche-spinoff developing small molecule antivirals. Previously, during his four-year tenure as Program Lead at Gilead Sciences, Inc., Dr. Pang led a large matrix team to the successful worldwide approval of the first one-pill, once-a-day hepatitis C treatment.

Dr. Pang received his bachelor’s degree in biological sciences from Stanford University and holds a Ph.D. in biochemistry and biophysics from Columbia University. His dissertation focused on viral molecular motors. He obtained his M.D. from Columbia University Vagelos College of Physicians and Surgeons, and completed his fellowship in infectious diseases at Stanford University.

What is Phillip Pang's net worth?: The estimated net worth of Phillip Pang is at least $1.78 million as of February 16th, 2024. Dr. Pang owns 264,679 shares of Vir Biotechnology stock worth more than $1,783,936 as of November 20th. This net worth approximation does not reflect any other investments that Dr. Pang may own. Learn More about Phillip Pang's net worth.
How do I contact Phillip Pang?: The corporate mailing address for Dr. Pang and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at [email protected]. Learn More on Phillip Pang's contact information.
Has Phillip Pang been buying or selling shares of Vir Biotechnology?: Phillip Pang has not been actively trading shares of Vir Biotechnology within the last three months. Most recently, Phillip Pang sold 3,321 shares of the business's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $10.24, for a transaction totalling $34,007.04. Following the completion of the sale, the executive vice president now directly owns 264,679 shares of the company's stock, valued at $2,710,312.96. Learn More on Phillip Pang's trading history.
Who are Vir Biotechnology's active insiders?: Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?: In the last twelve months, insiders at the sold shares 13 times. They sold a total of 172,771 shares worth more than $1,697,054.16. The most recent insider tranaction occured on November, 5th when EVP Verneuil Vanina De sold 2,347 shares worth more than $22,226.09. Insiders at Vir Biotechnology own 15.6% of the company. Learn More about insider trades at Vir Biotechnology.
Information on this page was last updated on 11/5/2024.

Phillip Pang Insider Trading History at Vir Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/16/2024	Sell	3,321	$10.24	$34,007.04	264,679
6/7/2023	Sell	5,000	$25.95	$129,750.00	188,000
2/23/2023	Sell	2,878	$25.97	$74,741.66	198,320
1/24/2023	Sell	30,000	$30.00	$900,000.00	144,000
7/20/2022	Sell	5,000	$30.00	$150,000.00	144,000
6/21/2022	Sell	4,991	$24.89	$124,225.99	144,000
2/16/2022	Sell	5,000	$31.54	$157,700.00
2/2/2022	Sell	5,000	$34.52	$172,600.00
1/19/2022	Sell	5,000	$35.06	$175,300.00
1/5/2022	Sell	5,000	$37.19	$185,950.00
12/15/2021	Sell	5,000	$50.72	$253,600.00
11/17/2021	Sell	5,000	$35.85	$179,250.00
11/3/2021	Sell	5,000	$36.47	$182,350.00
10/20/2021	Sell	4,000	$39.65	$158,600.00
10/6/2021	Sell	5,000	$34.56	$172,800.00
9/15/2021	Sell	5,000	$49.69	$248,450.00	104,997
9/1/2021	Sell	5,000	$49.58	$247,900.00
8/18/2021	Sell	5,000	$42.23	$211,150.00
8/4/2021	Sell	5,000	$34.92	$174,600.00	114,277
7/21/2021	Sell	4,630	$37.44	$173,347.20
7/7/2021	Sell	5,000	$40.39	$201,950.00	114,277
6/2/2021	Sell	10,000	$41.49	$414,900.00	119,277
10/21/2020	Sell	12,500	$35.49	$443,625.00	37,647
10/7/2020	Sell	12,500	$41.74	$521,750.00	39,962
9/16/2020	Sell	12,500	$31.90	$398,750.00	39,497
9/2/2020	Sell	12,500	$32.89	$411,125.00	42,277
8/19/2020	Sell	12,500	$50.95	$636,875.00	25,962
8/5/2020	Sell	12,500	$50.90	$636,250.00	28,277
7/15/2020	Sell	12,500	$49.53	$619,125.00	25,963
6/17/2020	Sell	12,500	$37.27	$465,875.00	28,277

Phillip Pang Buying and Selling Activity at Vir Biotechnology

Vir Biotechnology Company Overview

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Today's Range

Now: $6.74

$6.62

$7.03

50 Day Range

MA: $7.94

$6.74

$10.17

2 Week Range

Now: $6.74

$6.62

$13.09

Volume

1,473,682 shs

Average Volume

1,539,328 shs

Market Capitalization

$928.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.46

Blackrock’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW